COR-101
COVID-19 (Treatment & Prophylaxis)
Phase 1Active
Key Facts
About Corat Therapeutics
Corat Therapeutics is a private, preclinical/clinical-stage biotech developing fully human monoclonal antibodies for COVID-19. Its lead candidate, COR-101, demonstrated potent virus neutralization in preclinical models and entered clinical trials within a record 11 months of project initiation. The company positions its antibodies as a passive vaccine for immediate protection or treatment, targeting unmet needs in patient populations inadequately served by active vaccines. While currently focused on SARS-CoV-2, its antibody discovery platform could potentially be applied to other infectious diseases.
View full company profile